Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BYJ4

UPID:
TRI34_HUMAN

ALTERNATIVE NAMES:
Interferon-responsive finger protein 1; RING finger protein 21

ALTERNATIVE UPACC:
Q9BYJ4; D3DQS7; Q9C016; Q9HCR0; Q9HCR1; Q9HCR2

BACKGROUND:
The protein E3 ubiquitin-protein ligase TRIM34, with alternative names Interferon-responsive finger protein 1 and RING finger protein 21, is crucial for antiviral responses and cellular apoptosis. It restricts infection from non-host-adapted retroviruses, mediates virus-induced programmed necrosis, and negatively regulates mitochondrial function leading to apoptosis. TRIM34 also promotes cell fusion and phagocytosis, contributing to the immune response.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of E3 ubiquitin-protein ligase TRIM34 offers a promising avenue for therapeutic intervention. Its critical role in defending against retroviral infections and regulating apoptosis makes it a valuable target for the development of novel therapies aimed at controlling viral diseases and regulating cell death.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.